NCT06058702View on ClinicalTrials.gov

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

PHASE1RecruitingINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
SchizophreniaCannabis Use Disorder
Interventions
DRUG

Delta-9-THC Very Low Dose

Active Delta-9-THC administered intravenously over 20 minutes.

DRUG

Placebo

Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.

DRUG

Delta-9-THC Medium Dose

Active Delta-9-THC administered intravenously over 20 minutes.

Trial Locations (1)

06516

RECRUITING

West Haven Veterans Affairs Medical Center, West Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER